TNFSF8 Protein (AA 68-239, N-Term)

Catalog No. ABIN2666787

Recombinant TNFSF8 protein expressed in CHO Cells.

Quick Overview for TNFSF8 Protein (AA 68-239, N-Term) (ABIN2666787)

Target: TNFSF8 (Tumor Necrosis Factor (Ligand) Superfamily, Member 8 (TNFSF8))

Protein Type: Recombinant

Biological Activity: Active

Origin: Mouse

Source: CHO Cells

Application: Immunohistochemistry (IHC), Flow Cytometry (FACS)

Purity: > 95 % , as determined by Coomassie stained SDS-PAGE.

Product Details

Protein Characteristics: AA 68-239, N-Term

Sterility: 0.22 μm filtered

Endotoxin Level:

Less than 0.01 ng per μg cytokine as determined by the LAL method.

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Comment:

Biological activity: ED50 = 10 - 50 ng/ml, corresponding to a specific activity of 0.2 - 1.0 x 105 units/mg, as determined by induction of IL-6 in HDLM-2 human Hodgkin’s lymphoma cells.

Restrictions: For Research Use only

Handling

Format: Liquid

Reconstitution: For maximum results, quick spin vial prior to opening. Stock solutions should be prepared at no less than 10 μg/mL in sterile buffer (PBS, HPBS, DPBS, and EBSS) containing carrier protein such as 1 % BSA or HSA. After dilution, the cytokine can be stored between 2 °C and 8 °C for one month or from -20 °C to -70 °C for up to 3 months.

Buffer: 0.22 μm filtered protein solution is in PBS, pH 6.5.

Handling Advice: Avoid repeated freeze/thaw cycles.

Storage: -20 °C

Storage Comment: Unopened vial can be stored between 2°C and 8°C for three months, at -20°C for six months, or at -70°C for one year.

Target Details

Target: TNFSF8 (Tumor Necrosis Factor (Ligand) Superfamily, Member 8 (TNFSF8))

Alternative Name: CD30L

Background: CD30L is a type II membrane glycoprotein belonging to the TNFL superfamily, which includes CD27L (CD70), FasL (CD95L), OX40L (CD134L), 4-1BB ligand (CD137L), and CD40L (CD154). CD30 is a member of the TNF receptor superfamily, and it was originally identified as the cell surface antigen Ki-1, on Hodgkin and Reed-Sternberg cells. Recombinant murine CD30L shares functional properties with CD40L in the regulation of murine B cell growth and differentiation in vitro. CD30L stimulates B cell proliferation, antigen-specific antibody production, and polyclonal immunoglobulin secretion in a cytokine-dependent manner. IL-4 and IL-5 are required for B cell proliferation and IL-2 and IL-5 for antigen-specific immunoglobulin production. Interaction of CD30L, expressed in human B cells, with CD30+ T cells inhibits class switching and antibody production in human IgD+, IgM+ B cells. Cross-linking of CD30 ligand by a monoclonal antibody or by CD30-Fc fusion protein induces production of IL-8 from freshly isolated human neutrophils. The signaling induced from the receptor to the cell expressing the transmembrane protein is known as reverse signaling. CD30L/CD30 signaling seems to be involved in Th1 and Th2 cell responses and plays a key role in Th17 differentiation in mice. Mast cells are the predominant CD30L-positive cell in chronic inflammatory skin diseases such as psoriasis and atopic dermatitis. CD30 and CD30L expression is upregulated in lesional skin in these conditions.

Molecular Weight: The 193 amino acid recombinant protein has a predicted molecular mass of approximately 21.6 kDa. The DTT-reduced and non-reduced proteins migrate at approximately 40 - 50 kDa by SDS-PAGE. The predicted N-terminal amino acid is His.